![The Asian Pacific Association for the Study of the Liver [APASL]](https://www.apasl.info/wp-apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png){kind=logo}
APASL2014
Hepatitis C Direct Acting Antivirals for Genotypes 2/3: State of Play 2014
Direct Acting Antivirals for HCV GT-1 State of Play in 2014
Hepatitis C virus lifecycle: What are the best drug targets?
Optimizing triple therapy, and IFN/RBV free regimens
Public Health strategies to reduce liver disease in the Asia Pacific Region
Funding, access and infrastructure for new HCV therapies across Asia Pacific
Hepatitis C – Current Treatments: What Can We Offer Patients Now?
Drug Resistance and Treatment Failure in Asia
